Article
Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.
JCI insight - 23 Jun 2025
Sherman Shira, Sandusky Zachary M, Russo Douglas, Zak David, Nardone Agostina, Friel Delia, Hermida-Prado Francisco, Heraud Capucine, Kuziel Genevra, Verma Ana, Gaglia Giorgio, Kabraji Sheheryar, Nguyen Quang-De, Santagata Sandro, Fanning Sean W, Jeselsohn Rinath
Abstract excerpt
Estrogen receptor α (ER) is a critical driver of tumorigenesis and tumor progression in most breast cancers. Endocrine therapies (ET) targeting ER are central to treating hormone receptor-positive breast cancer, but resistance poses a clinical challenge. Some resistance mechanisms, particularly those involving estrogen-independent activity such as the ESR1 mutations, rely on ER signaling, supporting the need for...
Topics
Join the communities discussing this publication.